FAP and neoplasm: Although a cautious dose escalation strategy will need to be taken, as there may be some patients who may be more likely to experience on-target, off-tumor toxicity (for example in the case of an unknown fibrotic process), our data to date suggest that FAP-CAR T cell therapy will be safe.